Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study
暂无分享,去创建一个
E. Clementi | M. Menchetti | M. Nobile | E. Poluzzi | E. Raschi | F. De Ponti | S. Radice | M. Pozzi | C. Carnovale | V. Battini | M. Gringeri | M. Fusaroli | Valentina Giunchi | Roberto Rimodini | V. Giunchi
[1] G. Trifirò,et al. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database , 2022, Drug Safety.
[2] M. Menchetti,et al. Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System , 2022, The international journal of neuropsychopharmacology.
[3] E. Poluzzi,et al. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System , 2022, Drug Safety.
[4] I. Wilting,et al. Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase , 2022, European Neuropsychopharmacology.
[5] A. Lees,et al. Reply to 'Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.' , 2021, Parkinsonism & related disorders.
[6] Ç. Ermiş,et al. Selective serotonin reuptake inhibitors and manic switch: A pharmacovigilance and pharmacodynamical study. , 2021, Asian journal of psychiatry.
[7] T. Jhou. The rostromedial tegmental (RMTg) “brake” on dopamine and behavior: A decade of progress but also much unfinished work , 2021, Neuropharmacology.
[8] M. Menchetti,et al. Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list. , 2021, Parkinsonism & related disorders.
[9] D. Brooks,et al. Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study. , 2021, Parkinsonism & related disorders.
[10] A. Håkansson,et al. Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden , 2021, PloS one.
[11] T. Morera-Herreras,et al. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study , 2021, European Neuropsychopharmacology.
[12] N. Sousa,et al. Assessing Impulsivity in Humans and Rodents: Taking the Translational Road , 2021, Frontiers in Behavioral Neuroscience.
[13] B. Elfving,et al. Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task , 2021, Scientific Reports.
[14] C. Winstanley,et al. Impulse Control Disorders in Parkinson’s Disease: From Bench to Bedside , 2021, Frontiers in Neuroscience.
[15] E. Clementi,et al. Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review , 2021, The international journal of neuropsychopharmacology.
[16] C. Winstanley,et al. Pharmacological evidence of a cholinergic contribution to elevated impulsivity and risky decision-making caused by adding win-paired cues to a rat gambling task , 2021, Journal of psychopharmacology.
[17] K. Kaneda,et al. Role of 5-HT1A receptor-mediated serotonergic transmission in the medial prefrontal cortex in acute restraint stress-induced augmentation of rewarding memory of cocaine in mice , 2020, Neuroscience Letters.
[18] S. Leucht,et al. Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. , 2020, Schizophrenia bulletin.
[19] Minmin Luo,et al. Reward Contributions to Serotonergic Functions. , 2020, Annual review of neuroscience.
[20] C. Missale,et al. Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection , 2020, Biomolecules.
[21] J. Montastruc,et al. Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study , 2020, European Journal of Clinical Pharmacology.
[22] L. Wilkinson,et al. Effects of 5-HT2C, 5-HT1A receptor challenges and modafinil on the initiation and persistence of gambling behaviours , 2020, Psychopharmacology.
[23] J. Engelmann,et al. A neuroeconomic investigation of 5-HTT/5-HT1A gene variation, social anxiety, and risk-taking behavior , 2020, Anxiety, stress, and coping.
[24] S. Steidl,et al. Rewarding effects of M4 but not M3 muscarinic cholinergic receptor antagonism in the rostromedial tegmental nucleus , 2019, Behavioural Brain Research.
[25] E. Clementi,et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase® , 2019, Expert opinion on drug safety.
[26] D. Weintraub. Impulse control disorders in Parkinson's disease: A 20‐year odyssey , 2019, Movement disorders : official journal of the Movement Disorder Society.
[27] M. Lapeyre-Mestre,et al. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. , 2019, Therapie.
[28] Andrew R. Leach,et al. ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..
[29] E. Clementi,et al. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance–Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database , 2019, CNS Drugs.
[30] Stefano Tamburin,et al. Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies , 2018, Front. Neurol..
[31] P. Fletcher,et al. Dorsal raphe serotonin neurons inhibit operant responding for reward via inputs to the ventral tegmental area but not the nucleus accumbens: evidence from studies combining optogenetic stimulation and serotonin reuptake inhibition , 2018, Neuropsychopharmacology.
[32] P. Jolliet,et al. Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase , 2018, British journal of clinical pharmacology.
[33] G. Papazisis,et al. Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance‐pharmacodynamic study , 2018, British journal of clinical pharmacology.
[34] J. Montastruc,et al. Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological–Pharmacodynamic Study in VigiBase® , 2018, Drug Safety.
[35] M. Vidailhet,et al. Longitudinal analysis of impulse control disorders in Parkinson disease , 2018, Neurology.
[36] J. Wess,et al. Muscarinic M4 Receptors on Cholinergic and Dopamine D1 Receptor-Expressing Neurons Have Opposing Functionality for Positive Reinforcement and Influence Impulsivity , 2018, Front. Mol. Neurosci..
[37] O. Tysnes,et al. Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson’s Disease , 2018, Front. Neurol..
[38] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[39] K Domschke,et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 , 2017, Pharmacopsychiatry.
[40] P. Derkinderen,et al. Dopamine Agonists and Impulse Control Disorders: A Complex Association , 2017, Drug Safety.
[41] M. Lapeyre-Mestre,et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics , 2017, British journal of clinical pharmacology.
[42] D. Weintraub,et al. Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy , 2017, Seminars in Neurology.
[43] H. Fernandez,et al. Dopamine agonist withdrawal syndrome: A comprehensive review , 2017, Journal of the Neurological Sciences.
[44] O. Rascol,et al. An original pharmacoepidemiological–pharmacodynamic method: application to antipsychotic‐induced movement disorders , 2017, British journal of clinical pharmacology.
[45] N. Sousa,et al. Reappraising striatal D1- and D2-neurons in reward and aversion , 2016, Neuroscience & Biobehavioral Reviews.
[46] N. Costes,et al. Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study , 2016, Scientific Reports.
[47] M. Lapeyre-Mestre,et al. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase , 2015, European Neuropsychopharmacology.
[48] Robert M Sears,et al. Serotonin (5-HT) 5-HT2A Receptor (5-HT2AR):5-HT2CR Imbalance in Medial Prefrontal Cortex Associates with Motor Impulsivity. , 2015, ACS chemical neuroscience.
[49] P. Seeman. Parkinson's disease treatment may cause impulse–control disorder via dopamine D3 receptors , 2015, Synapse.
[50] J. Kauer,et al. Stress and VTA synapses: implications for addiction and depression , 2014, The European journal of neuroscience.
[51] C. Tung,et al. Acute and subchronic effects of buspirone on attention and impulsivity in the five-choice serial reaction time task in rats , 2013, Neuroscience Letters.
[52] Yu Ohmura,et al. Tandospirone suppresses impulsive action by possible blockade of the 5-HT1A receptor. , 2013, Journal of pharmacological sciences.
[53] C. Gremel,et al. Strengthening the accumbal indirect pathway promotes resilience to compulsive cocaine use , 2013, Nature Neuroscience.
[54] Marios Politis,et al. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. , 2013, Brain : a journal of neurology.
[55] Johan Hopstadius,et al. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery , 2011, Statistical methods in medical research.
[56] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[57] E. Hollander,et al. Impulse-control disorders not elsewhere classified. , 2012 .
[58] J. Tsien,et al. NMDA Receptors in Dopaminergic Neurons Are Crucial for Habit Learning , 2011, Neuron.
[59] A. Greenshaw,et al. 5-HT receptors and reward-related behaviour: A review , 2011, Neuroscience & Biobehavioral Reviews.
[60] R. Gainetdinov,et al. The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.
[61] K. Doya,et al. Activation of the central serotonergic system in response to delayed but not omitted rewards , 2011, The European journal of neuroscience.
[62] Rune W. Berg,et al. Influence of Phasic and Tonic Dopamine Release on Receptor Activation , 2010, The Journal of Neuroscience.
[63] G. Kranz,et al. Reward and the serotonergic system , 2010, Neuroscience.
[64] G. Juhász,et al. Significant association between the C(−1019)G functional polymorphism of the HTR1A gene and impulsivity , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[65] Ben M. Crittenden,et al. Dissociable Control of Impulsivity in Rats by Dopamine D2/3 Receptors in the Core and Shell Subregions of the Nucleus Accumbens , 2010, Neuropsychopharmacology.
[66] K. Deisseroth,et al. Phasic Firing in Dopaminergic Neurons Is Sufficient for Behavioral Conditioning , 2009, Science.
[67] Ming D. Li,et al. Significant association of DRD1 with nicotine dependence , 2008, Human Genetics.
[68] V. Voon,et al. Medication-related impulse control and repetitive behaviors in Parkinson disease. , 2007, Archives of neurology.
[69] Young T. Hong,et al. Nucleus Accumbens D2/3 Receptors Predict Trait Impulsivity and Cocaine Reinforcement , 2007, Science.
[70] A. Hoes,et al. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. , 2005, European heart journal.
[71] Y. P. Liu,et al. Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex , 2004, Psychopharmacology.
[72] J. Joyce,et al. Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons , 1999, Neuropsychopharmacology.
[73] D. Comings,et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors , 1997, Molecular Psychiatry.